Does inflammatory bowel disease cause IgA nephropathy?

Does Inflammatory Bowel Disease Cause IgA Nephropathy?

Yes, inflammatory bowel disease—particularly Crohn's disease—is associated with an increased risk of developing IgA nephropathy and should be recognized as a potential extra-intestinal manifestation of IBD.

The Evidence for Association

The 2016 European Consensus on Extra-Intestinal Manifestations in IBD explicitly states that "several cases of glomerulonephritis associated with IBD, including IgA nephropathy, have been reported, suggesting that it could be an EIM of IBD" 1. This guideline-level recognition establishes IgA nephropathy as a recognized complication of inflammatory bowel disease.

Epidemiologic Data Strongly Support This Link

Recent high-quality population studies confirm this association:

• A Japanese nationwide cohort of over 4.3 million individuals demonstrated that patients with IBD had nearly twice the risk of developing IgA nephropathy (HR 1.96; 95% CI 1.29-2.99) 2

• A Swedish population-based study of nearly 4,000 IgA nephropathy patients found that inflammatory bowel disease was 3.29 times more common in IgA nephropathy patients compared to matched controls (adjusted HR 3.29; 95% CI 2.73-3.96) 3

• Importantly, inflammatory bowel disease was more common both before and after the IgA nephropathy diagnosis, suggesting bidirectional or shared pathogenic mechanisms 3

Crohn's Disease Shows Stronger Association Than Ulcerative Colitis

The association is particularly pronounced with Crohn's disease rather than ulcerative colitis:

• Recent genetic and clinical studies demonstrate that Crohn's disease specifically shows consistent directional genetic association with IgA nephropathy across populations, while ulcerative colitis does not 4

• In a clinical cohort of 9,371 IBD patients, biopsy-confirmed IgA nephropathy was 3.4 times more common in Crohn's disease than ulcerative colitis (Firth-adjusted OR 3.40; 95% CI 1.28-11.28) 4

• Patients with Crohn's disease-associated IgA nephropathy exhibit a distinct phenotype with lower kidney function, higher serum IgA levels, and more severe tubulointerstitial injury compared to both ulcerative colitis-associated and non-IBD IgA nephropathy 5

Proposed Mechanisms: The Gut-Immune-Kidney Axis

The pathogenic link involves mucosal immune dysregulation affecting multiple organ systems:

• Both conditions share alterations in gut microbiota, with reduction in protective commensals and increase in pathogenic symbionts 6
• This leads to intestinal barrier disruption, promoting production of galactose-deficient IgA1 (Gd-IgA1) and activating intestinal mucosal immune cells 6
• Genetic studies have identified shared susceptibility genes, particularly ERAP2 and CARD9, supporting common inflammatory pathways 4
• Trafficking of immune cells from inflamed intestinal tissue to extra-intestinal mucosal surfaces may drive kidney inflammation 1

Critical Clinical Implications

Monitoring Requirements

All IBD patients—especially those with Crohn's disease—require regular renal surveillance:

• Monitor renal function every 3-12 months depending on risk factors 1
• Risk factors include: length of resected small bowel, disease duration, age, history of renal stones, and use of TNF-α inhibitors 1, 5
• The prevalence of renal insufficiency is reported as 2% in Crohn's disease patients and up to 15% in hospitalized IBD patients 1

Drug-Related Considerations

Be vigilant about medication-induced nephrotoxicity, which can complicate the picture:

• Sulfasalazine and 5-ASA can cause glomerulonephritis, nephrotic syndrome, and interstitial nephritis 7, 1
• Monitor renal function every 4 weeks during the first 3 months of 5-ASA therapy, then every 3 months for the first year, then annually 1
• TNF-α inhibitor use is more frequent in Crohn's disease-associated IgA nephropathy and may influence disease onset 5
• Ciclosporin can cause both acute and chronic renal impairment 1

Prognostic Impact

The presence of IBD worsens IgA nephropathy outcomes:

• Among IgA nephropathy patients, comorbid inflammatory bowel disease significantly increases the risk of progression to ESKD (HR 1.84; 95% CI 1.33-2.55) 3
• Crohn's disease-associated IgA nephropathy presents with lower eGFR and more advanced tubulointerstitial injury 5

Common Pitfalls to Avoid

1. Don't assume renal dysfunction is solely drug-related: While 5-ASA and other IBD medications can cause nephrotoxicity, true IgA nephropathy is a distinct entity requiring kidney biopsy for diagnosis

2. Don't wait for bowel disease activity to correlate with renal disease: Renal impairment can occur independently of intestinal disease activity 8

3. Don't overlook the need for kidney biopsy: There are no validated serum or urine biomarkers for IgA nephropathy diagnosis—biopsy remains essential 9

4. Don't forget that the association is bidirectional: Screen for IBD in patients presenting with IgA nephropathy, as inflammatory bowel disease may precede or follow the nephropathy diagnosis 3

The evidence clearly establishes that inflammatory bowel disease, particularly Crohn's disease, is causally associated with IgA nephropathy through shared mucosal immune dysregulation pathways, warranting systematic renal monitoring in all IBD patients.